Anne Flament

CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial

David A. Sallman, Tessa Kerre, Violaine Havelange et al. · The Lancet Haematology · 2023 · 83 citations · Full text

Hematological Malignancy, Cell Therapy, Dose Escalation Segment +11

Updated data from alloSHRINK phase I first-in-human study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC.

Hans Prenen, Jeroen Dekervel, Alain Hendlisz et al. · Journal of Clinical Oncology · 2021 · 41 citations

In Vivo Gene Therapy, Genetics, Immunology +28

Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

David A. Sallman, Jason Brayer, Xavier Poiré et al. · Blood · 2019 · 25 citations · Full text

Immunicy-1: Targeting BCMA with Cyad-211 to Establish Proof of Concept of an shRNA-Based Allogeneic CAR T Cell Therapy Platform

A. Samer Al‐Homsi, Sébastien Anguille, Dries Deeren et al. · Blood · 2021 · 23 citations

First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating Cyad-02, an Optimized Non Gene-Edited Engineered NKG2D CAR T-Cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Dries Deeren, Johan Maertens, Tara L. Lin et al. · Blood · 2020 · 20 citations